Premium Peptides To Buy Online

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration as outlined above.

• Peptide Vials (NAD+, 1000 mg each):
  • 8 weeks ≈ 6 vials (total 5,075 mg used)
  • 12 weeks ≈ 8 vials (total 7,875 mg used)
  • 16 weeks ≈ 11 vials (total 10,675 mg used)
• Insulin Syringes (U‑100, 1 mL):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
• Bacteriostatic Water (30mL bottles): Use 3.0 mL per vial for reconstitution.

Important Notes

Practical considerations for consistency, safety, and optimal results.

• Use new, sterile insulin syringes for each injection; dispose of used needles in a proper sharps container.
• Rotate injection sites systematically (abdomen at least 2 inches from navel, outer thighs, back of upper arms) to reduce soreness and prevent lipohypertrophy.
• Clean both the vial stopper and injection site with alcohol swabs; allow skin to air‑dry before injecting.
• Inject slowly over 5–10 seconds to minimize tissue irritation; wait a few seconds before withdrawing the needle.
• Document daily dose, injection site, and any observed effects to maintain consistency and track tolerance.
• If persistent redness or a lump develops at injection sites, apply over‑the‑counter hydrocortisone cream and rotate to a different location.
• Starting at the low end (50 mg) is recommended to assess individual tolerance before escalating dose

How This Works

NAD+ is a coenzyme central to redox reactions, energy metabolism (glycolysis, TCA cycle, oxidative phosphorylation), and cellular maintenance pathways including DNA repair and mitochondrial biogenesis^[1]. Cellular NAD+ levels decline with age and metabolic stress, which may contribute to reduced mitochondrial function and impaired cellular resilience

Clinical research on NAD+ therapy has primarily used intravenous infusions at high doses (500–1,000 mg) for applications such as addiction treatment and acute metabolic support. A pilot metabolic study demonstrated that a 750 mg NAD+ IV infusion over 6 hours was well‑tolerated in humans, with rapid metabolic clearance and no acute toxicity.  However, IV administration requires clinical supervision and specialized equipment.

Subcutaneous (SC) or intramuscular (IM) injections at lower doses (tens to low hundreds of milligrams) are emerging as practical alternatives for maintenance therapy and wellness applications. Compounded NAD+ can be administered SC in small volumes, and SC self‑injection is convenient for ongoing use. Conservative protocols start around 50–100 mg per injection a few times per week; the present protocol uses daily SC administration with gradual titration to optimize individual tolerance and response.

Potential Benefits & Side Effects

Observations from preclinical models and clinical case reports.

Potential Benefits (Reported in Literature)

• May support cellular energy production and mitochondrial function through replenishment of NAD+ pools
• Human case reports and pilot studies suggest benefits at 100–300 mg/day ranges for cognitive support and metabolic health